Editing

Prime Medicine is gearing up for a $200 million IPO.  We dug through the biotech's 282-page dossier to find 5 key points about the company's plan to commercialize gene editing.

Prime Medicine is gearing up for a $200 million IPO. We dug through the biotech’s 282-page dossier to find 5 key points about the company’s plan to commercialize gene editing.

Gene-editing biotech Prime Medicine filed for an IPO on Friday. Prime faces a freezing public market. The number of IPOs in the biotechnology sector decreased by 83% compared to last year. From a key patent to an uncertain timeline, here are five takeaways from Prime’s filing. Prime Medicine seeks to be the first gene-editing biotech …

Prime Medicine is gearing up for a $200 million IPO. We dug through the biotech’s 282-page dossier to find 5 key points about the company’s plan to commercialize gene editing. Read More »

Chroma Medicine Announces Formation of Scientific Advisory Board of Global Experts in Gene Editing and Cell and Gene Therapy

Chroma Medicine Announces Formation of Scientific Advisory Board of Global Experts in Gene Editing and Cell and Gene Therapy

Members Bradley BernsteinMD, Ph.D., Paula Canondoctorate, howard changMD, Ph.D., and Ahmad (Mo) KhalilPh.D., will guide the advancement of the company’s epigenetic editing platform and key programs Scientific Advisors Join Chroma Founders, Luke Gilbertdoctorate, Keith Young MD., Ph.D., David Liudoctorate, Angelo Lombardodoctorate, Luigi NaldiniMD, Ph.D., and jonathan weismanPh.D., expanding the company’s world-class team of genomic medicine …

Chroma Medicine Announces Formation of Scientific Advisory Board of Global Experts in Gene Editing and Cell and Gene Therapy Read More »